The association of baseline sarcoidosis measurements with 6-month outcomes that are of interest to patients: Results from the On-line Sarcoidosis Assessment Platform Study (OSAP) - 20/04/22
, Recai Yucel b, Sara Preston c, Edward S. Chen d, Daniel A. Culver e, Nabeel Hamzeh f, Elyse E. Lower g, Nadera J. Sweiss h, Dominique Valeyre i, Marcel Veltkamp j, David E. Victorson k, Jennifer L. Beaumont l, Noopur Singh m, Tricha Shivas m, Rachel Vancavage a, Robert P. Baughman gAbstract |
Introduction |
The impact of common measures to assess sarcoidosis have not been compared longitudinally to outcomes that are meaningful to patients. We prospectively examined the relationship of baseline measurements of sarcoidosis status to outcomes of interest to patients longitudinally over 6 months.
Methods |
Sarcoidosis patients cared for at 6 US medical centers were “phenotyped” at baseline with measurements of pulmonary function, organ involvement, health related quality of life (HRQoL) instruments, and their anti-sarcoidosis treatment history. These patients were followed for 6 months by monitoring outcomes of interest to patients (OIPs) including steps walked, calories expended, sleep, HRQoL measures, workdays missed and health care utilization. For each baseline phenotypic measurement, patients were dichotomized into two groups above and below a specified cutoff value. The area under the OIP versus time curve was compared between these two groups.
Results |
The cutoff values for many baseline phenotypic measures distinguished the patients into groups with significantly different 6-month OIPs. The chosen cutoff for the patient global estimate of health status distinguished the most OIPs (13/15). The 6-min walk distance cutoff was associated with more OIPs than spirometric measures. All of the HRQOL measure cutoffs were associated with many OIPs, although most of them were other HRQOL measures.
Interpretation |
Cutoffs for most of the phenotypic measures used to assess sarcoidosis distinguished groups of sarcoidosis patients with differing OIPs over the subsequent 6 months. The patients’ global assessment of their disease was the most accurate of these measures.
Clinical trial registration number |
NCT04342403.
Le texte complet de cet article est disponible en PDF.Keywords : Sarcoidosis, Health-related quality of life, Outcomes, Pulmonary function, Patient assessment, Treatment, Sarcoidosis organ involvement
Plan
Vol 196
Article 106819- mai 2022 Retour au numéro
Article précédent
- Incidence of depression and antidepressant prescription in patients with COPD: A large UK population-based cohort study
- R.A. Siraj, T.M. McKeever, J.E. Gibson, C.E. Bolton
- Trends in sarcoidosis mortality rate in Japan from 2001 to 2020: A population-based study
- Ko Harada, Hideharu Hagiya, Toshihiro Koyama, Fumio Otsuka
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?